Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues    
Royalty $ 0 $ 2,112
Product 90,035 11,321
Total Revenues 90,035 13,433
Operating Expenses    
Research and development 15,541,889 14,533,862
General and administrative 8,751,392 5,654,018
Sales and marketing 4,129,833 1,073,368
Total Operating Expenses 28,423,114 21,261,248
Operating Loss (28,333,079) (21,247,815)
Other Income (Expenses)    
Grant income 1,522,533 635,513
(Loss)/Gain on disposal of fixed assets (26,166) 293,312
Interest income 2,734 49,495
Interest expense (155,803) (129,799)
Total Other Income (Expenses) 1,343,298 848,521
Net Loss (26,989,781) (20,399,294)
Net Loss attributable to Non-Controlling Interest 175,116 47,179
Net Loss attributable to VolitionRx Limited Stockholders (26,814,665) (20,352,115)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 208,304 (185,648)
Net Comprehensive Loss $ (26,781,477) $ (20,584,942)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders $ (0.51) $ (0.45)
Weighted Average Shares Outstanding    
- Basic and Diluted 52,655,885 45,278,847